Osang Healthcare Co.,Ltd
Financials
Valuation Metrics
Osang Healthcare Co.,Ltd's Market Cap is ₩966B. At end of 2025 it was ₩1694B. Ranked #1302 of 2,421 in KR market (top 54%), #716 of 1,640 on KOSDAQ (top 44%), #47 of 96 in Health Care Equipment & Services (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 96.59B KRW | KR#1,302/2,421 Sec#47/96 |
| Revenue | 96.48B KRW | KR#1,436/2,421 Sec#40/96 |
| Net Income | -8.48B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 341.88B KRW | KR#967/2,421 Sec#19/96 |
| Net Assets | 279.58B KRW | KR#749/2,421 Sec#16/96 |
| Employees | 343 | KR#698/2,421 Sec#17/96 |
| Value | ||
| P/B | 0.35x | KR#431/2,421 Sec#5/96 |
| P/S | 1.00x | KR#1,393/2,421 Sec#27/96 |
| FCF Yield | -10.23% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -3.03% | KR#1,722/2,421 Sec#58/96 |
| ROA | -2.48% | KR#1,791/2,421 Sec#60/96 |
| Op. Margin | -21.27% | KR#2,135/2,421 Sec#70/96 |
| Revenue Growth | -15.35% | KR#2,046/2,421 Sec#85/96 |
| Earnings Growth | -224.61% | KR#1,248/2,421 Sec#45/96 |
| Financial Health | ||
| Debt Ratio | 22.28% | KR#424/2,421 Sec#24/96 |
| Total Debt | 43.42B KRW | KR#1,056/2,421 Sec#26/96 |
| FCF | -9.88B KRW | KR#1,705/2,421 Sec#62/96 |
| Cash | 17.14B KRW | KR#1,341/2,421 Sec#37/96 |
| Current Ratio | 2.37x | KR#728/2,421 Sec#41/96 |
| Dividend | ||
| Div. Yield | 2.96% | KR#642/2,421 Sec#10/96 |
| Div. Growth | -60.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -57.52% | KR#2,172/2,421 Sec#78/96 |
| 1M Return | -0.44% | KR#1,289/2,421 Sec#39/96 |
| From 52W High | -60.01% | KR#1,858/2,421 Sec#62/96 |
| 1Y MDD | -67.47% | KR#1,862/2,421 Sec#64/96 |
| Trading | ||
| Volume | 34,953 shares | KR#1,300/2,421 Sec#46/96 |
| Trading Value | 236.4M KRW | KR#1,210/2,421 Sec#45/96 |
| Foreign Own. | 1.12% | KR#1,988/2,421 Sec#74/96 |
| Per Share | ||
| EPS | -592 KRW | KR—/2,421 Sec—/96 |
| BPS | 19,538 KRW | KR#547/2,421 Sec#7/96 |
Company Info
Established in 1996, Osang Healthcare develops, produces, and sells biochemical, immunoassay, and molecular diagnostic products in the in-vitro diagnostics field, and was listed on KOSDAQ in 2024. With the new consolidation of OSANG COSMETIC LTDA, a Brazilian cosmetic distribution company, in 2025, the company now holds three subsidiaries. Its product portfolio includes self-blood glucose meters and POCT HbA1c meters for biochemical diagnostics; SelexOn and COVID-19 self-test kits for immunoassay diagnostics; and PCR-based Genefinder products for molecular diagnostics. Osang Healthcare is headquartered in Anyang-si, Gyeonggi-do.